GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

tinlarebant   Click here for help

GtoPdb Ligand ID: 14262

Synonyms: BPN-14967 | BPN14967 | compound 81 [WO2015168286] | LBS-008 | LBS008
Compound class: Synthetic organic
Comment: Tinlarebant (LBS-008; formerly BPN-14967) is an orally bioactive retinol binding protein 4 (RBP4) antagonist. It is proposed to reduce accumulation of lipofuscin (which contains cytotoxic bisretinoids) that drives degenerative retinal diseases [1,3].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 65.01
Molecular weight 456.41
XLogP 2.14
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC(=O)N1CCC2=C(C1)NN=C2C(=O)N3CCC(CC3)C4=CC=C(C(=C4C(F)(F)F)F)F
Isomeric SMILES CC(=O)N1CCC2=C(C1)NN=C2C(=O)N3CCC(CC3)C4=C(C(=C(C=C4)F)F)C(F)(F)F
InChI InChI=1S/C21H21F5N4O2/c1-11(31)30-9-6-14-16(10-30)27-28-19(14)20(32)29-7-4-12(5-8-29)13-2-3-15(22)18(23)17(13)21(24,25)26/h2-3,12H,4-10H2,1H3,(H,27,28)
InChI Key HAGSLCBZFRRBLS-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Chou HD, Hwang YS, Chen KJ, Wu WC, Liu L, Ou ST, Liao W, Wang CC, Lin T, Lai CC. (2023)
Analysis of Retinol Binding Protein 4 and ABCA4 Gene Variation in Non-Neovascular Age-Related Macular Degeneration.
Diagnostics (Basel), 13 (14). [PMID:37510153]
2. Cioffi C, Johnson G, Allikmets R, Chen P, Conlon M, Zhu L. (2015)
Substituted 4-phenylpiperidines, their preparaiton and use.
Patent number: WO2015168286A1. Assignee: Trustees Of Columbia University In The City Of New York, Petrukhin K, Freeman E. Priority date: 29/04/2015. Publication date: 05/11/2015.
3. Petrukhin K. (2013)
Pharmacological inhibition of lipofuscin accumulation in the retina as a therapeutic strategy for dry AMD treatment.
Drug Discov Today Ther Strateg, 10 (1): e11-e20. [PMID:25152755]